Conditional Survival in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab

BACKGROUND: Nivolumab is approved for the treatment of advanced renal cell carcinoma (RCC). However, traditional overall survival (OS) or progression-free survival (PFS) do not reflect patient prognosis after initial management. Therefore, this study aimed to evaluate conditional overall survival (C...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Ning, Wan, Fangning, Zhu, Yao, Ye, Dingwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2019
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738006/
https://www.ncbi.nlm.nih.gov/pubmed/31469816
http://dx.doi.org/10.12659/MSM.916984

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738006/
https://www.ncbi.nlm.nih.gov/pubmed/31469816
http://dx.doi.org/10.12659/MSM.916984

Ejemplares similares